AIM Operations

Important Clinical Links

Remote Access/NYP App Store

Soarian (on campus or on VPN only - for off campus use App Store above)

NYS Prescription Monitoring Program/iSTOP


Columbia Library (for access to journal articles off campus)

PIC Feedback Tool

Latest News from AIM

Diabetes Management Clinic changes and the return of DSME! 

We’re excited to announce that Angelica Santana RD is joining AIM as a diabetes educator. In the mornings she will be seeing together with residents in Diabetes Management Clinic.  In the afternoons she will provide diabetes self-management education and training to all of our patient with diabetes. To summarize:

Diabetes Management clinic (previously with a resident and pharmD):

The clinic will be staffed by a resident who can titrate medications and Angelica who will provide education.

  • Who to refer: Patients with poorly controlled diabetes (A1c >9)
  • When does it meet: Every morning
  • How to refer: “Onsite Service Referral – Diabetes Management Pharmacist” (stay tuned for an updated referral name soon)

Diabetes Self-Management Education (DSME):

Angelica will have afternoon sessions to meet individually with patients and provide self-management education that targets patient specific barriers.

  • Who to refer: Any patient with diabetes
  • When does it meet: Every afternoon (except Thursday)
  • How to refer: “Diabetes self-management education/training (DSME/T)” order - NOT THE REFERRAL IN THE AIM ORDER SET

Social work update

A belated welcome to Marlen Gonzalez who joins the 207 team as a social worker!  She has previously worked at Mt. Sinai and in the outpatient clinical setting.  She’s bilingual and a great addition to our team. We’re excited to have her on board.

Ambulatory Read of the Week

The Accomplish Trial

An oldy but a goody. The only trial comparing cardiovascular outcomes for specific combinations of BP meds, this RCT demonstrated a decrease in major adverse cardiovascular events for amlodipine and benazepril compared to HCTZ and benazepril (9.6% vs 11.8%, HR 0.80, P < 0.001). Food for thought! Some questions raised by this trial (courtesy of the Uptodate page):

  • Is the ACE/dihydropyridine calcium channel blocker (A/dC) combination the preferred regimen in previously untreated patients who require two drugs because they are more than 20/10 mmHg above goal?
  • Should patients being treated with the combination of an ACE inhibitor/ARB and a thiazide diuretic who are at goal and doing well be switched to A/dC? Approximately 75 percent of patients in ACCOMPLISH had previously been treated with two or more antihypertensive drugs.
  • In patients being treated with and having responded to a thiazide diuretic who require a second antihypertensive drug, should the thiazide be discontinued and the patient started on A/dC?
  • Does ACCOMPLISH affect the choice of monotherapy, with a long-acting ACE inhibitor/ARB or a long-acting dihydropyridine calcium channel blocker being preferred so that the second class can be added if the patient responds but does not reach goal with the initial drug?